Table 2.
Number and proportions of patients who achieved humoral response at week 5 by subgroup
| PCV-13 | TTV | |
|---|---|---|
| Overall baricitinib group (N = 106) | 70 (68) | 44 (43) |
| Concomitant corticosteroids | ||
| Yes (N = 31) | 22 (71) | 16 (52) |
| No (N = 72) | 48 (67) | 28 (39) |
| Age group | ||
| Patients < 65 years (N = 80) | 59 (74) | 37 (46) |
| Patients ≥ 65 years (N = 23) | 11 (48) | 7 (32) |
| SDAI prior to vaccination | ||
| ≤ 3.3 (N = 21) | 13 (62) | 11 (55) |
| > 3.3 and ≤ 11 (N = 47) | 34 (72) | 20 (43) |
| > 11 (N = 32) | 21 (66) | 13 (41) |
| Baricitinib dose | ||
| 2 mg (N = 16) | 11 (69) | 5 (33) |
| 4 mg (N = 87) | 59 (68) | 39 (45) |
Data are reported as n (%). PCV-13 satisfactory humoral response defined as a ≥ 2-fold increase from baseline in antibody concentrations in ≥ 6 of the 13 pneumococcal serotypes. TTV satisfactory humoral response defined as a ≥ 4-fold increase from baseline in anti-tetanus concentration in patients with baseline anti-tetanus IgG concentration ≥ 0.1 IU/mL
PCV-13 13-serotype pneumococcal conjugate vaccine, SDAI Simplified Disease Activity Index, TTV tetanus toxoid vaccine